Cetera Advisors’s Charles River Laboratories CRL Stock Holding History

Cetera Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$910K	Buy	3,357 +2,227	+197%	+$532K	0.01%	1209
2023 Q4	$267K	Buy	+1,130	New	+$222K	﹤0.01%	1491
2023 Q3	–	Sell	-966	Closed	-$203K	–	1725
2023 Q2	$203K	Buy	+966	New	+$192K	﹤0.01%	1503
2023 Q1	–	Sell	-1,055	Closed	-$230K	–	1664
2022 Q4	$230K	Buy	+1,055	New	+$230K	﹤0.01%	1374
2022 Q2	–	Sell	-750	Closed	-$213K	–	1387
2022 Q1	$213K	Sell	750 -230	-23%	-$70.9K	﹤0.01%	1283
2021 Q4	$369K	Sell	980 -515	-34%	-$200K	0.01%	1017
2021 Q3	$617K	Buy	1,495 +755	+102%	+$314K	0.01%	799
2021 Q2	$274K	Buy	740 +7	+1%	+$2.34K	0.01%	1096
2021 Q1	$212K	Buy	+733	New	+$204K	0.01%	1123

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Cetera Advisors's CRL Position: Q1 2024 in Review

Cetera Advisors increased its Charles River Laboratories (CRL) stake by 197% in Q1 2024, buying an estimated $532K and bringing the position to 3,357 shares worth $910K. The position accounts for 0.01% of the portfolio, ranked #1209.

Cetera Advisors first reported a position in CRL in Q1 2021 and has held it in 9 quarters since. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

Cetera Advisors held 3,357 shares of Charles River Laboratories worth $910K as of Q1 2024.
Cetera Advisors bought 2,227 Charles River Laboratories shares in Q1 2024, an estimated $532K.
Charles River Laboratories made up 0.01% of Cetera Advisors's portfolio in Q1 2024, its #1209 holding.
Cetera Advisors first reported a position in Charles River Laboratories in Q1 2021 and has held it in 9 quarters since.
676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.